Safety evaluation of 43 patients with no grade 3 or higher treatment-related adverse eventsFLORHAM PARK, N.J., Aug. 04, 2022 (GLOBE...
Nes-Ziona, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...
Study will evaluate safety and tolerability of AGEN1571 as a single agent and in combination with botensilimab and balstilimab Preclinical...
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery...
Conference Call on Tuesday, August 9, 2022 at 8:30 a.m. ETLEXINGTON, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ:...
-- Tumor control was achieved in four of ten evaluable patients with advanced solid tumors unresponsive to other treatments enrolled...
AURELIO-04 will enroll up to 320 patients and test the combination in multiple solid tumor indicationsClinical collaborator, MSD (Merck &...
NORCROSS, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins,...
FLORHAM PARK, N.J., July 26, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from...
Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase 1/2 trial to commence by early...
Addition of Immunotherapeutic Agent Under Investigation for the Treatment of Ovarian Cancer to Asset PortfolioTAMPA, Fla., July 22, 2022 (GLOBE...
HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapiesTOKYO,...
€4 million ($4.2 million) research and innovation award for consortium to develop first-in-class smart bioprocessing manufacturing platformLONDON, July 21, 2022...
Research will leverage Artizan’s proprietary IgA-SEQ™ discovery platform to identify gut microbiota that may affect the safety and efficacy of...
European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural...
--6th Orphan Drug Designation granted to toripalimab in the US and EU SHANGHAI, China, July 21, 2022 (GLOBE NEWSWIRE) --...
ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs’ Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA...
Basel, 21 July 2022 Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Division sales...